Lexaria Bioscience(LEXX)
$4.03-0.46 (-10.24%)
LEXX
Lexaria Bioscience financials statements
$4.03
At close:-0.46 (-10.24%)
Lexaria Bioscience (LEXX) Ratios
252 Followers
Lexaria Bioscience Ratios
LEXX's free cash flow for Q3 2026 was $-1.66M. For the 2026 fiscal year, LEXX's free cash flow was decreased by $-26.25K and operating cash flow was $-1.64M. See a summary of the company’s cash flow.
| Ratios | Aug 25 | Aug 24 | Aug 23 | Aug 22 | Aug 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.32 | 7.18 | 8.22 | 35.96 | 81.18 |
| Quick Ratio | 2.32 | 7.18 | 8.22 | 35.76 | 80.99 |
| Cash Ratio | 1.21 | 5.91 | 5.05 | 29.96 | 71.23 |
| Solvency Ratio | -7.51 | -4.73 | -16.14 | -35.36 | -19.09 |
| Operating Cash Flow Ratio | -7.00 | -4.51 | -21.97 | -25.15 | -26.03 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | -503.37 |
| Net Current Asset Value | $ 1.90M | $ 6.69M | $ 1.80M | $ 6.78M | $ 12.24M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.02 | 0.05 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | 0.04 | 0.02 | 0.05 | 0.01 | 0.01 |
| Debt-to-Capital Ratio | 0.04 | 0.02 | 0.05 | 0.01 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.40 | 1.10 | 1.01 | 0.99 | 1.00 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -506.76 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.09 | 0.01 | 0.02 | 0.01 | 0.02 |
| Net Debt to EBITDA | 0.14 | 1.11 | 0.18 | 0.80 | 2.69 |
| Profitability Margins | |||||
| Gross Profit Margin | 99.61% | 82.56% | 23.86% | 18.29% | 75.74% |
| EBIT Margin | -1687.36% | -1251.12% | -2967.41% | -2891.06% | -576.16% |
| EBITDA Margin | -1674.91% | -1234.71% | -2903.14% | -2833.54% | -555.74% |
| Operating Profit Margin | -1683.01% | -1226.70% | -2888.50% | -2545.40% | -763.84% |
| Pretax Profit Margin | -1687.36% | -1251.12% | -2967.41% | -2891.06% | -576.16% |
| Net Profit Margin | -1686.00% | -1248.25% | -2946.36% | -2846.30% | -557.19% |
| Continuous Operations Profit Margin | -1687.36% | -1251.12% | -2967.41% | -2891.06% | -576.16% |
| Net Income Per EBT | 99.92% | 99.77% | 99.29% | 98.45% | 96.71% |
| EBT Per EBIT | 100.26% | 101.99% | 102.73% | 113.58% | 75.43% |
| Return on Assets (ROA) | -285.07% | -65.35% | -216.11% | -92.79% | -30.35% |
| Return on Equity (ROE) | -398.10% | -72.11% | -218.94% | -91.45% | -30.36% |
| Return on Capital Employed (ROCE) | -443.04% | -73.31% | -232.01% | -85.09% | -42.10% |
| Return on Invested Capital (ROIC) | -438.07% | -73.05% | -229.74% | -84.62% | -41.95% |
| Return on Tangible Assets | -307.76% | -69.40% | -254.25% | -98.96% | -31.21% |
| Earnings Yield | -75.14% | -11.97% | -95.97% | -41.73% | -14.74% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.06 | 3.01 | 1.29 | 1.27 | 2.11 |
| Payables Turnover | 0.00 | 0.08 | 0.77 | 1.74 | 1.67 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 5.43 | 5.91 |
| Fixed Asset Turnover | 2.11 | 1.19 | 0.54 | 0.69 | 1.57 |
| Asset Turnover | 0.17 | 0.05 | 0.07 | 0.03 | 0.05 |
| Working Capital Turnover Ratio | 0.16 | 0.11 | 0.05 | 0.03 | 0.10 |
| Cash Conversion Cycle | -183086.89 | -4647.02 | -194.10 | 145.43 | 16.29 |
| Days of Sales Outstanding | 89.97 | 121.44 | 282.77 | 288.38 | 172.92 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 67.20 | 61.72 |
| Days of Payables Outstanding | 183176.86 | 4768.47 | 476.87 | 210.14 | 218.34 |
| Operating Cycle | 89.97 | 121.44 | 282.77 | 355.58 | 234.64 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -8.71 | -0.40 | -0.89 | -0.83 | -0.91 |
| Free Cash Flow Per Share | -8.73 | -0.40 | -0.91 | -0.84 | -0.93 |
| Dividend Paid and CapEx Coverage Ratio | -424.07 | -115.28 | -34.68 | -99.19 | -50.19 |
| Capital Expenditure Coverage Ratio | -424.07 | -115.28 | -34.68 | -99.19 | -50.19 |
| Operating Cash Flow Coverage Ratio | -95.59 | -36.10 | -35.87 | -97.61 | -41.00 |
| Operating Cash Flow to Sales Ratio | -14.80 | -10.68 | -26.00 | -19.10 | -5.52 |
| Free Cash Flow Yield | -66.13% | -10.33% | -87.13% | -28.29% | -14.90% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.33 | -8.36 | -1.04 | -2.40 | -6.78 |
| Price-to-Sales (P/S) Ratio | 22.44 | 104.29 | 30.70 | 68.21 | 37.79 |
| Price-to-Book (P/B) Ratio | 5.30 | 6.03 | 2.28 | 2.19 | 2.06 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.51 | -9.68 | -1.15 | -3.53 | -6.71 |
| Price-to-Operating Cash Flow Ratio | -1.52 | -9.76 | -1.18 | -3.57 | -6.85 |
| Price-to-Earnings Growth (PEG) Ratio | -0.03 | 0.16 | 0.06 | -0.07 | 0.19 |
| Enterprise Value Multiple | -1.20 | -7.34 | -0.88 | -1.61 | -4.11 |
| Enterprise Value | 14.15M | 42.06M | 5.76M | 11.66M | 16.49M |
| EV to EBITDA | -1.20 | -7.34 | -0.88 | -1.61 | -4.11 |
| EV to Sales | 20.04 | 90.59 | 25.45 | 45.64 | 22.82 |
| EV to Free Cash Flow | -1.35 | -8.41 | -0.95 | -2.37 | -4.05 |
| EV to Operating Cash Flow | -1.35 | -8.48 | -0.98 | -2.39 | -4.13 |
| Tangible Book Value Per Share | 1.91 | 0.58 | 0.34 | 1.21 | 2.89 |
| Shareholders’ Equity Per Share | 2.49 | 0.65 | 0.46 | 1.35 | 3.02 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.59 | 0.04 | 0.03 | 0.04 | 0.16 |
| Net Income Per Share | -9.92 | -0.47 | -1.01 | -1.24 | -0.92 |
| Tax Burden | 1.00 | 1.00 | 0.99 | 0.98 | 0.97 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 11.67 | 5.08 | 16.21 | 7.21 | 1.75 |
| SG&A to Revenue | 6.16 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 1.22 | 1.06 | 0.75 | 2.95 | 0.57 |
| Income Quality | 0.88 | 0.85 | 0.88 | 0.66 | 0.95 |
Currency in USD

